# Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

> **NCT03912818** · PHASE2 · TERMINATED · sponsor: **Stanford University** · enrollment: 7 (actual)

## Conditions studied

- Bladder Adenocarcinoma
- Bladder Mixed Adenocarcinoma
- Bladder Squamous Cell Carcinoma
- Bladder Urothelial Carcinoma
- Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant
- Infiltrating Bladder Urothelial Carcinoma With Giant Cells
- Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation
- Infiltrating Bladder Urothelial Carcinoma With Trophoblastic Differentiation
- Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant
- Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant
- Infiltrating Bladder Urothelial Carcinoma, Nested Variant
- Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **PROCEDURE:** Cystectomy
- **DRUG:** Doxorubicin
- **BIOLOGICAL:** Durvalumab
- **DRUG:** Gemcitabine
- **DRUG:** Methotrexate
- **DRUG:** Vinblastine

## Key facts

- **NCT ID:** NCT03912818
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-04-10
- **Primary completion:** 2022-08-11
- **Final completion:** 2022-08-11
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Difficulty with enrollment
- **Last updated:** 2023-09-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03912818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03912818, "Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03912818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*